Berubicin receives FDA Orphan Drug status for gliomas

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Berubicin was granted Orphan Drug Designation by FDA for the treatment of malignant gliomas.

Berubicin is sponsored by CNS Pharmaceuticals Inc.

In the phase I trial of Berubicin to treat glioblastoma under a prior developer, 44% of the patients demonstrated a significant improvement in progression-free survival, and one patient experienced a complete response.

Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login